aTYR PHARMA INC Finance Lease, Right-of-Use Asset, after Accumulated Amortization
aTYR PHARMA INC (ATYR) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $298.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-07
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $298.00K.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $447.00K.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $596.00K.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $745.00K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2026-06-30 | $298.00K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $447.00K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $596.00K 10-Q · filed 2026-08-07 |
| 2025-09-30 | $745.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $894.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.04M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $1.19M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.34M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.49M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.64M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.79M 10-K · filed 2025-03-13 |
| 2023-09-30 | $1.79M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.89M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $1.95M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $1.25M 10-K · filed 2024-03-14 |
| 2022-09-30 | $768.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $368.00K 10-Q · filed 2022-08-15 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |